FR18C1008I2 - Regime posologique de cladribine pour le traitement de la sclerose en plaques - Google Patents
Regime posologique de cladribine pour le traitement de la sclerose en plaquesInfo
- Publication number
- FR18C1008I2 FR18C1008I2 FR18C1008C FR18C1008C FR18C1008I2 FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2 FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 C FR18C1008 C FR 18C1008C FR 18C1008 I2 FR18C1008 I2 FR 18C1008I2
- Authority
- FR
- France
- Prior art keywords
- cladribine
- treatment
- multiple sclerosis
- dosage regimen
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 title 1
- 229960002436 cladribine Drugs 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63866904P | 2004-12-22 | 2004-12-22 | |
| EP04106909 | 2004-12-22 | ||
| PCT/EP2005/056954 WO2006067141A1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
| EP05823474A EP1827461B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR18C1008I1 FR18C1008I1 (enExample) | 2018-03-30 |
| FR18C1008I2 true FR18C1008I2 (fr) | 2019-03-01 |
Family
ID=36227798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR18C1008C Active FR18C1008I2 (fr) | 2004-12-22 | 2018-02-14 | Regime posologique de cladribine pour le traitement de la sclerose en plaques |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7713947B2 (enExample) |
| EP (7) | EP3332789B1 (enExample) |
| JP (7) | JP5795456B2 (enExample) |
| KR (1) | KR20070091662A (enExample) |
| AR (1) | AR052830A1 (enExample) |
| AU (2) | AU2005318190B2 (enExample) |
| BR (1) | BRPI0517132B8 (enExample) |
| CA (2) | CA2588966C (enExample) |
| CY (3) | CY1112614T1 (enExample) |
| DK (3) | DK3332789T3 (enExample) |
| EA (1) | EA015799B1 (enExample) |
| ES (2) | ES2921858T3 (enExample) |
| FI (1) | FI4070800T3 (enExample) |
| FR (1) | FR18C1008I2 (enExample) |
| HR (1) | HRP20120228T1 (enExample) |
| HU (3) | HUE070333T2 (enExample) |
| IL (2) | IL183930A0 (enExample) |
| LT (3) | LT4070800T (enExample) |
| LU (1) | LUC00064I2 (enExample) |
| MX (1) | MX2007007610A (enExample) |
| NO (1) | NO20073813L (enExample) |
| PL (4) | PL2805723T3 (enExample) |
| SG (1) | SG160391A1 (enExample) |
| SI (3) | SI2805723T1 (enExample) |
| WO (1) | WO2006067141A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0517132B8 (pt) | 2004-12-22 | 2021-05-25 | Laboratoires Serono S A | uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla |
| CA2649810A1 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
| EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
| WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
| WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
| GB201401465D0 (en) | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
| GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
| CN119097635A (zh) * | 2017-11-24 | 2024-12-10 | 默克专利股份公司 | 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法 |
| US20240226284A1 (en) | 2020-09-10 | 2024-07-11 | Merck Patent Gmbh | Novel treatment regimen for the treatment of autoimmune disorders |
| GB2601786A (en) * | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
| US5310732A (en) * | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
| US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
| US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
| US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
| JPH10512549A (ja) | 1994-12-22 | 1998-12-02 | オーソ・フアーマシユーチカル・コーポレーシヨン | 可溶性の２−クロロ−２’−デオキシアデノシン配合物 |
| US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
| WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
| DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
| EP1556400B1 (en) | 2002-09-25 | 2013-05-01 | Brigham Young University | Method for the preparation of 2-halo-2 -deoxyadenosine compounds from 2 -deoxyguanosine |
| GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
| EP1596873A1 (en) * | 2003-02-25 | 2005-11-23 | Applied Research Systems ARS Holding N.V. | Combined use of ribavirin and interferon beta in demyelinating diseases |
| ES2584183T3 (es) | 2003-03-28 | 2016-09-26 | Ares Trading S.A. | Formulaciones de cladribina para suministro mejorado oral y transmucosa |
| HRP20050925A2 (en) | 2003-03-28 | 2006-08-31 | Ivax Corporation | Oral formulations of cladribine |
| BRPI0517132B8 (pt) | 2004-12-22 | 2021-05-25 | Laboratoires Serono S A | uso de cladribina para preparação de uma formulação farmacêutica para tratamento de esclerose múltipla |
| CA2649810A1 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en not_active Expired - Lifetime
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en not_active Expired - Lifetime
- 2005-12-20 FI FIEP22166610.0T patent/FI4070800T3/fi active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es not_active Expired - Lifetime
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 SI SI200532321T patent/SI4070800T1/sl unknown
- 2005-12-20 EP EP24206496.2A patent/EP4523753A3/en not_active Withdrawn
- 2005-12-20 LT LTEP22166610.0T patent/LT4070800T/lt unknown
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en not_active Ceased
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Ceased
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en not_active Expired - Lifetime
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja not_active Expired - Lifetime
- 2005-12-20 HU HUE22166610A patent/HUE070333T2/hu unknown
- 2005-12-20 DK DK22166610.0T patent/DK4070800T3/da active
- 2005-12-20 CA CA2588966A patent/CA2588966C/en not_active Expired - Lifetime
- 2005-12-20 PL PL22166610.0T patent/PL4070800T3/pl unknown
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en not_active Expired
- 2005-12-20 ES ES22166610T patent/ES3007339T3/es not_active Expired - Lifetime
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en not_active Expired - Lifetime
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 EP EP22166610.0A patent/EP4070800B1/en not_active Revoked
- 2005-12-20 CA CA3087419A patent/CA3087419C/en not_active Expired - Lifetime
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en not_active Expired
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja not_active Expired - Lifetime
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja not_active Expired - Lifetime
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja not_active Expired - Lifetime
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja not_active Expired - Lifetime
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I2/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR23C1003I2 (fr) | Compositions et leurs utilisations pour le traitement de la Sclérose en plaques | |
| EP2059210A4 (en) | THERAPEUTIC DEVICES FOR TREATING VARIOUS WOMEN'S DRESS | |
| EP1931691A4 (en) | ODKASE INHIBITORS FOR THE TREATMENT OF MALARIA | |
| EP1838320A4 (en) | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS | |
| EP1951272A4 (en) | USE OF LACTOBACILLUS FOR THE TREATMENT OF VIRUS INFECTIONS | |
| EP1985302A4 (en) | DRUGS FOR TUMOR THERAPY AND ITS USE | |
| EP2313146A4 (en) | DEVICES FOR TREATING VASCULAR ANEURYSMA | |
| EP2773643A4 (en) | PAK HEMMER FOR TREATING FRAGILEM X SYNDROME | |
| LTPA2018503I1 (lt) | Kladribino režimas, skirtas išsėtinei sklerozei gydyti | |
| EP2164501A4 (en) | SULFATED XYLANE FOR THE TREATMENT OR PROPHYLAXIS OF RESPIRATORY DISEASES | |
| EP2442832A4 (en) | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS | |
| PL2205720T3 (pl) | Kompozycja do leczenia stwardnienia rozsianego | |
| EP2207892A4 (en) | METHOD FOR SELECTION OF ACTIVE AGENTS FOR CANCER TREATMENT | |
| EP2144632A4 (en) | SYNTHETIC HERPES SIMPLEX VIRUS TYPE 1 FOR TUMOR TREATMENT | |
| FR2962041B1 (fr) | Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies | |
| EP2389180A4 (en) | METHOD FOR THE TREATMENT OF MUSCLE DYSTROPHIES | |
| EP1773970A4 (en) | LUBRICANT FORMULATIONS FOR PANEL PROCESSING | |
| FR2907011B1 (fr) | Utilisation de la citrulline pour le traitement des etats de denutrition | |
| EP2015741A4 (en) | HISTONDEACETYLASE INHIBITORS FOR THE TREATMENT OF NEURODE GENERATION | |
| EP1832861A4 (en) | COMPONENT FOR PRE-ANALYTICAL TREATMENT | |
| EP1732549A4 (en) | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES | |
| EP1889618A4 (en) | Combined drug for treating diabetes | |
| FR2886153B1 (fr) | Composition destinee au traitement de la sclerose en plaques | |
| EP2099303A4 (en) | THERAPEUTIC COMPOSITIONS ON TETRAHYDROISOCHINOLINE BASE FOR CANCER THERAPY | |
| FR2875404B1 (fr) | Composition pharmaceutique pour le traitement de la rosacee |